PT-141
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
PT-141, known generically as bremelanotide, is a synthetic peptide studied for sexual dysfunction. It is a melanocortin-receptor agonist derived from research on alpha-melanocyte-stimulating hormone, and it acts centrally — in the brain — rather than on the vascular system.
Bremelanotide is notable because, unlike most research peptides, it has completed the FDA approval process. Under the brand name Vyleesi, it is approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is important to distinguish this regulated, prescribed medication from material sold on the research-chemical market as “PT-141,” which is not an approved product and is not subject to the same manufacturing and quality controls.
How it works
Bremelanotide is an agonist at melanocortin receptors, activating them non-selectively — including the MC4 receptor, which is thought to play a role in sexual desire and arousal pathways in the central nervous system. This central mechanism sets it apart from erectile-dysfunction drugs, which work by increasing blood flow.
The precise way this receptor activity translates into changes in sexual desire is not fully understood. Regulators note that the exact mechanism of action for its approved indication remains uncertain, even though the receptor target is well characterized.
Reported benefits
- Increased sexual desire in premenopausal women with HSDD (clinical trial data)
- Reduced distress associated with low sexual desire
- A central, on-demand mechanism that does not rely on hormonal changes or blood flow
These are reported effects studied in specific populations, not guaranteed outcomes for everyone.
Considerations & side effects
In clinical trials, the most commonly reported side effects were nausea, flushing, and headache. Most were mild to moderate and transient, though nausea was frequent enough that some participants discontinued. Bremelanotide has also been associated with temporary increases in blood pressure and darkening of the skin or gums with repeated use.
The safety data that exists comes from studies of the approved product in premenopausal women. Research-chemical “PT-141” sold outside that context has not been evaluated for purity or safety, and outcomes may differ. This information is educational and is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is PT-141?
PT-141 is another name for bremelanotide, a synthetic melanocortin-receptor agonist studied for sexual dysfunction. It acts on the central nervous system rather than on blood flow, unlike erectile-dysfunction drugs.
Is PT-141 FDA-approved?
Bremelanotide is FDA-approved under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Material sold as research-chemical 'PT-141' is a separate, unapproved product and is not the same as a prescribed, regulated medication.
How does PT-141 differ from erectile-dysfunction medications?
It works through a different pathway. Rather than increasing blood flow like PDE5 inhibitors, bremelanotide activates melanocortin receptors in the brain that are thought to be involved in sexual desire and arousal.
How is bremelanotide administered?
The approved product is given as a subcutaneous injection with an autoinjector, used ahead of anticipated sexual activity. Research-chemical PT-141 is also typically injected after reconstitution.
References
- Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006. ↗
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019. ↗
- Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019. ↗
- Edinoff AN, et al. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurol Int. 2022. ↗
Related compounds
Sexual-health blend pairing the melanocortin agonist PT-141 (bremelanotide), which drives arousal and desire, with oxytocin, associated with bonding and intimacy. Sold as a single co-lyophilized vial.
Neuropeptide that stimulates GnRH release, triggering natural testosterone and reproductive hormone production. Used for hormonal assessment and reproductive health support.
Naturally occurring hormone involved in social bonding, mood regulation, and reproductive function. Administered as nasal spray for anxiolytic and social benefits.